公費疫苗
Mycobacterium tuberculosis disease prevention

Vaccine, Live (Bacterial)

1. Prior hypersensitivity to the vaccine or any component of the formulation
2. Immunosuppressed patients or persons with congenital or acquired immune deficiencies (eg, HIV infection, leukemia, lymphoma, cancer therapy, immunosuppressive therapy such as corticosteroids)
3. Active tuberculosis

BCG vaccine is not recommended for use in pregnant women.

Due to the potential for serious adverse reactions in the nursing infant, a decision should be made to discontinue breastfeeding or avoid use of BCG vaccine, taking into account the importance of BCG vaccination to the mother.

Dermatologic: Pustules (at injection site), skin ulceration at injection site
Hematologic & oncologic: Cervical lymphadenopathy, lymphadenitis (includes local and suppurative), lymphadenopathy (axillary)
Infection: BCG infection (BCG osteomyelitis; may occur from 4 months to 2 years after vaccination)
Local: Induration at injection site, injection site lesion, itching at injection site, tenderness at injection site
Respiratory: Flu-like symptoms

Immunization against tuberculosis: Percutaneous 0.2-0.3 mL (full-strength dilution); conduct postvaccinal tuberculin test in 2 to 3 months; if test is negative, repeat vaccination.

There are no dosage adjustments provided in the manufacturer's labeling.

There are no dosage adjustments provided in the manufacturer's labeling.